Physician profile
Peter Y Ma
NPI 1902831019
$2,643.31
in general payments reported to CMS, 2019-2025
18 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $193 · 2021: $191 · 2022: $125 · 2023: $595 · 2024: $575 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,601.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $380.08 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $324.24 | 2019-2024 | |
| Gilead Sciences, INC. | $292.80 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $205.00 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $186.92 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $166.89 | 2022-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.04 | 2023-2025 | Jardiance |
| Medtronic Vascular, INC. | $144.49 | 2020 | |
| Glaxosmithkline, LLC. | $144.16 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $132.69 | 2024-2025 | |
| Medtronic, INC. | $130.15 | 2021 | |
| Corium, LLC | $125.00 | 2023 | Adlarity |
| Lilly USA, LLC | $93.42 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $49.55 | 2024 | |
| Vivus LLC | $42.00 | 2023-2025 | Pancreaze |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.27 | 2025 | Gardasil 9, Capvaxive |
| Ironwood Pharmaceuticals, INC | $23.04 | 2023 | Linzess |
| Lundbeck LLC | $19.57 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Ma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.